NCT04393038Phase 2, phase 3Terminated

ABX464 in Treating Inflammation and Preventing Acute Respiratory Failure in Patients With COVID-19

Study sponsor: Abivax S.A. · ABVX

Compare the available registry edits below. Primary completion is the date data collection ends for the main study measures; it does not tell you when results will be published.

Primary completion2021-03-05Actual
Enrollment · participants509Actual
Source updated2025-11-26Last update listed in the registry record
Version history

Changes to this trial

Last 12 months
Pro unlocks the full available history and CSV export. View Pro features

· 1 field changed

Primary outcomes · main study measures

Text edit · unverified significance
− Previous value

measure: Rate of patients with no invasive or non-invasive mechanical ventilation (IMV and NIV, respectively), but excluding simple nasal/mask oxygen supplementation, and who are alive

+ Updated value

measure: Rate of Responders: i.e. Rate of Patients Who do Not Require Use of High-flow Oxygen Invasive or Non-invasive Mechanical Ventilation (IMV and NIV, Respectively) Within 28 Days and Who Are Alive at the End of the 28 Days Period.

The saved outcome text may be shortened. Check the source for full wording.

Check registry source